Sign in

Private company

BIOCEPT INC

American medical laboratories services company based in San Diego2

In its 2023 annual report the company says: “We are a molecular oncology diagnostics company with a history of net losses; we expect to incur net losses in the future, and we may never achieve sustained profitability.”58

Last updated Oct 21, 2026.

Overview

  • IndustryServices-Medical Laboratories2
  • HeadquartersSan Diego, United States2
  • Incorporated inDE3
  • Business address9955 Mesa Rim Road, San Diego, Ca 921213
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI5493000MP9GU5S88NF422
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O Corporation Service Company, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 53416312

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-123.7%Operating margin4
-124.1%Net margin4
-57.8%Revenue growth, 20224
-362.2%Return on equity4
-$14.1MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue81¢$28.4M
  • Research and development18¢$6.2M
  • Interest1¢$316.0K
  • Income tax0¢$125.0K

Out of $25.9M in revenue.4 The company lost money this year.

Financial statements

Revenue567894$25.9M in 2022+702% since 2016
0$20.0M$40.0M$60.0M$80.0M2016: $3.2M$3.2M20162017: $5.1M$5.1M2017+57%2018: $3.3M$3.3M2018−36%2019: $5.5M$5.5M2019+70%2020: $27.5M$27.5M2020+397%2021: $61.2M$61.2M2021+123%2022: $25.9M$25.9M2022−58%
Operating income567894-$32.0M in 2022+77% since 2016
-$40.0M-$30.0M-$20.0M-$10.0M02016: -$18.0M-$18.0M20162017: -$21.2M-$21.2M2017+17%2018: -$24.3M-$24.3M2018+15%2019: -$23.1M-$23.1M2019−5%2020: -$15.5M-$15.5M2020−33%2021: -$2.4M-$2.4M2021−84%2022: -$32.0M-$32.0M2022+1228%
Net income567894-$32.1M in 2022+74% since 2016
-$40.0M-$30.0M-$20.0M-$10.0M02016: -$18.4M-$18.4M20162017: -$21.6M-$21.6M2017+17%2018: -$24.6M-$24.6M2018+14%2019: -$25.1M-$25.1M2019+2%2020: -$17.8M-$17.8M2020−29%2021: -$2.8M-$2.8M2021−84%2022: -$32.1M-$32.1M2022+1036%
Fiscal year2016201720182019202020212022
Revenue$3.2M5$5.1M6$3.3M7$5.5M8$27.5M9$61.2M4$25.9M4
Cost of revenue$6.9M5$9.3M6$10.1M7$11.0M8$21.3M9$37.8M4$28.4M4
Gross profit
Research and development$2.7M5$3.4M6$4.5M7$4.7M8$5.2M9$5.0M4$6.2M4
Operating expenses$63.7M4$57.8M4
Operating income-$18.0M5-$21.2M6-$24.3M7-$23.1M8-$15.5M9-$2.4M4-$32.0M4
Interest$525.9K5$482.6K6$311.0K7$250.0K8$236.0K9$290.0K4$316.0K4
Income before tax-$2.7M4-$32.2M4
Income tax$2.1K5$7.6K6$1.9K7$125.0K4-$125.0K4
Net income-$18.4M5-$21.6M6-$24.6M7-$25.1M8-$17.8M9-$2.8M4-$32.1M4
Earnings per share-$1.925-$23.586-$9.017-$12.238-$1.509-$0.194-$1.894
Earnings per share (diluted)-$1.925-$23.586-$9.017-$12.238-$1.509-$0.194-$1.894
Shares (weighted, basic)14.8M shares417.0M shares4
Shares (weighted, diluted)14.8M shares417.0M shares4

Compare BIOCEPT INC with another company

Corporate structure

BIOCEPT INC sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of BIOCEPT INC

  • BIOCEPT INC San Diego, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What BIOCEPT INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Machinery and equipment$3.2M4 Dec 31, 2022$3.1M4 Dec 31, 2021+3.9%
Furniture and fixtures$160.0K4 Dec 31, 2022$161.0K4 Dec 31, 2021−0.6%
Leasehold improvements$689.0K4 Dec 31, 2022$634.0K4 Dec 31, 2021+8.7%
Construction in progress$39.0K4 Dec 31, 2022$245.0K4 Dec 31, 2021−84.1%
Property and equipment, before depreciation$7.9M4 Dec 31, 2022$7.0M4 Dec 31, 2021+12.2%
Accumulated depreciation$5.3M4 Dec 31, 2022$4.6M4 Dec 31, 2021+14.9%
Property and equipment, net$2.6M4 Dec 31, 2022$2.4M4 Dec 31, 2021+7.1%
Finance-lease assets$3.1M4 Dec 31, 2022$2.8M4 Dec 31, 2021+8.6%
Operating-lease assets (leased space)$8.5M4 Dec 31, 2022$9.0M4 Dec 31, 2021−6.0%

Inventory

ItemLatestA year beforeChange
Inventory, total$757.0K4 Dec 31, 2022$2.7M4 Dec 31, 2021−71.4%
Raw materials$1.6M4 Dec 31, 2022$2.5M4 Dec 31, 2021−37.1%
Work in process$401.0K4 Dec 31, 2022$324.0K4 Dec 31, 2021+23.8%
Finished goods$36.0K4 Dec 31, 2022$42.0K4 Dec 31, 2021−14.3%

Leadership

Who has led BIOCEPT INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Michael W. Nall2014–2021
  2. Samuel D. Riccitelli2022

Chair

  1. David F. Hale2014–2015

President

  1. Michael W. Nall2014–2021
  2. Samuel D. Riccitelli2022

Chief financial officer

  1. William G. Kachioff2014
  2. Mark G. Foletta2015
  3. Timothy Kennedy2016–2021
  4. Antonino Morales2022

Chief operating officer

  1. Timothy Kennedy2021
201520202025
Board members and other officers (23)

Timeline

  1. Oct 20, 20238-K Listing notice or transfer42
  2. Oct 16, 20238-K Bankruptcy or receivership; Executive or director change43
  3. Aug 22, 20238-K Results of operations44
  4. Jun 21, 20238-K Executive or director change45
  5. May 16, 20238-K Change to shareholders' rights46
  6. May 15, 20238-K Results of operations; Listing notice or transfer; Shareholder vote47
  7. Apr 17, 20238-K Earlier financial statements no longer reliable48
  8. Apr 17, 20238-K Results of operations49
  9. Apr 10, 20238-K Entered a material agreement; Unregistered sale of shares; Change to shareholders' rights50
  10. Mar 20, 20238-K Executive or director change51
  11. Jan 6, 20238-K Results of operations; Exit or restructuring costs; Other events52
  12. Nov 21, 20228-K Results of operations53
  13. Mar 2, 2022New chief executive Samuel D. Riccitelli becomes CEO12
  14. Feb 4, 2014New chief executive Michael W. Nall becomes CEO13
  15. Jun 28, 2013Founded BIOCEPT INC is founded2

Calendar

When it reported results

  1. Aug 22, 2023Reported quarterly or annual results44
  2. May 15, 2023Reported quarterly or annual results47
  3. Apr 17, 2023Reported quarterly or annual results49
  4. Jan 6, 2023Reported quarterly or annual results52
  5. Nov 21, 2022Reported quarterly or annual results53
  6. Nov 14, 2022Reported quarterly or annual results54
  7. May 24, 2022Reported quarterly or annual results55
  8. Apr 7, 2022Reported quarterly or annual results56

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

88 filings to the SEC since October 2021: 2 annual reports, 8 quarterly reports, 30 major events, 16 insider forms, 1 large holders, 31 other. The latest 20:

  1. Nov 20, 202325-NSE EDGAR
  2. Oct 20, 20238-K EDGAR
  3. Oct 16, 20238-K EDGAR
  4. Aug 22, 20238-K EDGAR
  5. Aug 14, 202310-Q EDGAR
  6. Jun 21, 20238-K EDGAR
  7. Jun 20, 20233 FORM 3 SUBMISSION EDGAR
  8. Jun 2, 2023SC 13G EDGAR
  9. May 25, 2023424B4 EDGAR
  10. May 24, 2023EFFECT EDGAR
  11. May 23, 2023CORRESP EDGAR
  12. May 23, 2023CORRESP EDGAR
  13. May 23, 2023S-1/A EDGAR
  14. May 19, 2023CORRESP EDGAR
  15. May 19, 2023CORRESP EDGAR
  16. May 19, 2023S-1/A EDGAR
  17. May 18, 2023CORRESP EDGAR
  18. May 18, 2023CORRESP EDGAR
  19. May 16, 2023CORRESP EDGAR
  20. May 16, 2023CORRESP EDGAR

The 88 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 0 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 9, 2021HALE DAVID FDirectorSale445$4.06$1.8KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How BIOCEPT INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBIOCEPT INC1
  • CIK0001044378
  • Employer ID (EIN)80-09435221
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)8071 Services-Medical Laboratories1
  • Business address9955 Mesa Rim Road, San Diego, CA 921211
  • Phone858-320-82001
  • Shares outstanding2,626,026 as of Aug 8, 202311
  • Public float$15.9M as of Jun 30, 20224
  • On EDGAR sinceOct 1, 20021
  • Filings616 in all: 4 (154), 8-K (119), CORRESP (43), S-1/A (32), 10-Q (29), 3 (29), UPLOAD (20), EFFECT (16)1
    All 42 form types

    SC 13G (16), 424B5 (12), DEF 14A (11), REGDEX (11), S-1 (11), S-8 (11), 10-K (10), 424B3 (10), D (10), SC 13G/A (10), 424B4 (8), DEFA14A (8), 8-K/A (4), PRE 14A (4), S-3 (4), 3/A (3), FWP (3), NT 10-Q (3), S-1MEF (3), SC 13D/A (3), 10-K/A (2), 10-Q/A (2), NT 10-K (2), POS AM (2), REGDEX/A (2), 25-NSE (1), 4/A (1), 8-A12B (1), CERTNAS (1), CT ORDER (1), DEFR14A (1), DRS (1), POS EX (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Apr 17, 2023
    Quarterly report (10-Q) Aug 14, 2023
    Proxy statement (DEF 14A) Apr 20, 2023
    Latest 8-K (8-K) Oct 20, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58